Medicover stock
MCOV-B.STSTOMedicover AB (publ), HealthcareISIN SE0009778848
61Score 61 out of 100, Neutral
Price and trend
74 / 100
Price history
+8.0% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 17% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 32).
The price is 7.2% below its 52-week high. Largest decline in 9 years: 70% (December 2021 to September 2022).
Chart figures for advanced users
- SMA 50$26.10
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$22.61
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)32
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$18.27
- The lowest closing price of the last twelve months.
- Resistance$28.43
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Medicover AB (publ) belongs to the Medical (Care Facilities) industry (Sweden) and, with a market value of $4.01B, is number 20 of 57 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.64B (up 13.7% year on year) and earnings of $85.88M (up 364.1%).
- MEQIRI Score 61 out of 100 (Neutral): rank 256 of 702 in Healthcare, median 53.
Show more
- The P/E is 39.9 (Medical (Care Facilities) median 19.6, own median of recent years 60.6).
- Our model puts fair value at $16.44, with the price 60% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 214% of earnings over the last 12 months.Fundamentals 83
- Earnings per share growingUp 23.2% a year since 2020.Growth 91
- Growing faster than its industryRevenue up 19% a year since 2020, Medical (Care Facilities) median 9.2%.Growth 91
Weaknesses
- High debtDebt 2.26 times equity (latest quarter), Medical (Care Facilities) median 0.96.Stability 38
- Above fair valuePrice 60% above the fair value of $16.44.Valuation 36
- Interest barely coveredOperating profit covers interest only 2.5 times.Stability 38
Its standout strengths are growth and fundamentals, while valuation and capital allocation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 62 to 61.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- solid fundamentals
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $12.65 and expensive above $23.48 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $19.89 (cash-flow model) and $12.99 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 7.1%. At 8.1% the fair value would be $14.91, at 6.1% it would be $18.73.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 5.1% on the twelve months before. Revenue has grown strongly since 2014, at around 19% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 23%, operating 7%, net 3%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 10 Feb 2027in 89 days
- Last reported
- 4 Nov 2026EPS reported 1.8 (expected 1.86)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 3.1% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- 0.62−4.0%
- Revenue
- $2.7B−3.9%
- Earnings per share
- 0.84−3.1%
- Revenue
- $2.82B−7.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −1.1%The midterm targets to 2028 remain confirmed: organic revenue of EUR 3.25 billion and adjusted EBITDA of EUR 600 million.
“So organic revenue of EUR 3.25 billion, adjusted organic EBITDA of EUR 600 million, leverage under 3x and all the other measures highlighted in the bottom right corner, including EBIT, we expect to achieve that.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 22 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Medicover
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 61
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Concentra Group Holdings ParentCON $5.44B69
- LifeStance Health GroupLFST $5.38B57
- Option Care HealthOPCH $4.75B64
- Hims & Hers HealthHIMS $4.44B35
- Acadia HealthcareACHC $3.52B48
- Surgery PartnersSGRY $3.48B53
- National HealthCareNHC $3.3B68
- Guardian Pharmacy ServicesGRDN $3.13B77
ETFs that hold Medicover
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares OMX Stockholm Capped UCITS ETFOM3X | 0.22% | 0.10% | €198.93M |
| iShares Ageing Population UCITS ETF2B77 | 0.18% | 0.40% | €813.42M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.12% | 0.30% | €3.45B |
Show 5 more
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.06% | 0.30% | €813.64M |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.03% | 0.23% | €321.86M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.02% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729, $1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 27 Jun 2025)
- Valuation signal Overvalued since 8 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.